FindTrial
Sign In

Efficacy of immune checkpoint inhibitors in patients with MSI-H/dMMR small bowel adenocarcinoma

Efficacy of immune checkpoint inhibitors in patients with MSI-H/dMMR small bowel adenocarcinoma - Efficacy of immune checkpoint inhibitors in patients with MSI-H/dMMR small bowel adenocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000058372
Enrollment
Unknown
Registered
2025-07-07
Start date
2025-07-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MSI-H/dMMR small bowel adenocarcinoma

Interventions

None listed

Sponsors

Toyohashi Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) The search terms include "small bowel adenocarcinoma", "non-colorectal", "solid tumor", "MSI-H", "dMMR", "immunotherapy", "immune checkpoint", "programmed cell death protein 1", "programmed cell death ligand 1 inhibitor", "PD-1" and "PD-L1". (2) Single-arm Phase I-III clinical trials evaluating immunotherapy in patients with advanced SBA or solid tumors, reporting objective response rates or treatment outcomes for individual patients.

Exclusion criteria

Exclusion criteria: (1) Observational or retrospective studies. (2) Systematic review or meta-analysis studies. (3) Studiers published in languages other than English. (6) Conference abstracts.

Design outcomes

Primary

MeasureTime frame
Objective response rate of immune checkpoint inhibitors in MSI-H/dMMR small bowel adenocarcinoma—

Countries

Japan

Contacts

Public ContactYu Nakashima

Toyohashi Municipal Hospital Department of General Surgery

nakashima-yu@toyohashi-mh.jp81-532-33-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026